NEW YORK (GenomeWeb) – T2 Biosystems announced after the close of the market today that it has begun a public offering of 3.5 million shares of its common stock.

The company also said it expects to grant the underwriters of the offering a 30-day option to buy an additional 525,000 shares at the public offering price. Goldman Sachs is acting as the book-running manager for the offering. Additional underwriters include Leerink Partners, Canaccord Genuity, and Cantor Fitzgerald.

T2's stock closed at $11.77 in Tuesday trade on the Nasdaq.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

British Nobel laureates and Fields Medal winners warn that a 'hard' Brexit could harm science across the UK, the Guardian reports.

Vox reports on inequities in genetic research and efforts to address them.

The New York Times reports that Arizona State University's Lawrence Krauss is retiring following allegations of sexual misconduct.

In PNAS this week: de novo NUS1 mutations linked to Parkinson's disease risk, candidate hepatocellular carcinoma drivers, and more.